Stabilized Cone Snail Venom Peptide Shows Promise as Non-Opioid Pain Treatment
Conformationally constrained α-RgIA analogues maintain potent and selective antagonism of human α9α10 nicotinic receptors with enhanced serum stability, offering non-opioid pain drug candidates.
Quick Facts
What This Study Found
Lactam-bridged α-RgIA analogues maintained high potency and selectivity for human α9α10 nAChR with enhanced serum stability. NMR confirmed the macrocyclic peptide preserves the native conformation. Molecular docking rationalized selective binding.
Key Numbers
Constrained analogs: high potency, receptor selectivity, enhanced human serum stability vs natural alpha-RgIA.
How They Did This
Peptide synthesis with lactam bridge introduction. Electrophysiology for receptor potency and selectivity. NMR structure determination. Serum stability assays. Molecular docking modeling for binding rationalization.
Why This Research Matters
Non-opioid pain treatments are urgently needed. This work transforms a fragile natural venom peptide into a stable drug candidate by solving its key pharmaceutical weakness — instability — while maintaining its desirable pharmacological properties.
The Bigger Picture
Cone snail venoms have already yielded one FDA-approved pain drug (ziconotide/Prialt). This stabilization approach could unlock more venom-derived peptides as practical therapeutics, expanding the non-opioid pain treatment arsenal.
What This Study Doesn't Tell Us
In vitro receptor and stability studies — no in vivo pain model testing reported. Route of administration for clinical use uncertain (venom peptides often require intrathecal delivery). Manufacturing costs of constrained peptides may be prohibitive.
Questions This Raises
- ?Do these stabilized peptides show analgesic efficacy in animal pain models?
- ?Can they be administered systemically rather than intrathecally?
- ?Would this lactam stabilization approach work for other venom-derived peptide drug candidates?
Trust & Context
- Key Stat:
- Enhanced stability lactam bridge fixes peptide conformation and suppresses disulfide scrambling, improving serum half-life
- Evidence Grade:
- Rigorous in vitro pharmacological characterization with structural validation. Promising drug candidate but pre-animal testing stage.
- Study Age:
- Published in 2020. Venom-derived peptide therapeutics remain an active area of analgesic drug development.
- Original Title:
- Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors.
- Published In:
- Journal of medicinal chemistry, 63(15), 8380-8387 (2020)
- Authors:
- Zheng, Nan(3), Christensen, Sean B, Blakely, Alan, Dowell, Cheryl, Purushottam, Landa, McIntosh, J Michael, Chou, Danny Hung-Chieh
- Database ID:
- RPEP-05241
Evidence Hierarchy
Frequently Asked Questions
How do cone snail venom peptides treat pain?
Cone snail venoms contain peptides that precisely target specific pain-related receptors. One venom peptide (ziconotide) is already FDA-approved for severe chronic pain. The α9α10 nicotinic receptor targeted here is involved in neuropathic pain.
What makes these peptides non-addictive?
Unlike opioids that act on reward pathways in the brain, these peptides target nicotinic receptors specifically involved in pain signaling. They provide pain relief through a completely different mechanism that doesn't trigger the dopamine-driven addiction cycle.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05241APA
Zheng, Nan; Christensen, Sean B; Blakely, Alan; Dowell, Cheryl; Purushottam, Landa; McIntosh, J Michael; Chou, Danny Hung-Chieh. (2020). Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors.. Journal of medicinal chemistry, 63(15), 8380-8387. https://doi.org/10.1021/acs.jmedchem.0c00613
MLA
Zheng, Nan, et al. "Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors.." Journal of medicinal chemistry, 2020. https://doi.org/10.1021/acs.jmedchem.0c00613
RethinkPeptides
RethinkPeptides Research Database. "Development of Conformationally Constrained α-RgIA Analogues..." RPEP-05241. Retrieved from https://rethinkpeptides.com/research/zheng-2020-development-of-conformationally-constrained
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.